MORE VIDEOS
Explore more

Lung Cancer - Non-Small Cell

Non-small Cell Lung Cancer Explained – stage 1
Non-small Cell Lung Cancer Explained – stage 1 administrator 2 Views • 2 years ago

A guide to what you need to know about Stage I Lung Cancer.
A patient’s perspective on biomarker testing in non-small cell lung cancer
A patient’s perspective on biomarker testing in non-small cell lung cancer administrator 3 Views • 2 years ago

Lung cancer patient Cindy Griffin highlights her own experience as well as the impact that her diagnosis had on her family. She discusses the importance of biomarker testing in lung cancer and how learning about her genetic mutation changed her treatment journey.

To learn more about Cindy’s story, visit: https://www.novartis.com/stori....es/patient-perspecti

© 2018 Novartis AG

Case Study: Treating an Elderly Patient With Squamous Non-Small Cell Lung Cancer
Case Study: Treating an Elderly Patient With Squamous Non-Small Cell Lung Cancer administrator 4 Views • 2 years ago

In the first installment of the series, moderator Corey J. Langer, MD, introduces the panelists and begins a case-based discussion that details the diagnosis and treatment of an elderly patient with squamous cell NSCLC.

To view more from this discussion, visit http://www.onclive.com/peer-ex....change/nsclc-therapi

PD-L1 Testing in Non-Small Cell Lung Carcinoma
PD-L1 Testing in Non-Small Cell Lung Carcinoma administrator 1 Views • 2 years ago

In this month’s “Hot Topic,” Anja Roden, M.D., will discuss the role of PD-L1 interaction in the immune system, challenges with PD-L1 testing, and current PD-L1 testing in Non-Small Cell Lunch Carcinoma (NSCLC).
Non–Small Cell Lung Cancer: Other Actionable Mutations
Non–Small Cell Lung Cancer: Other Actionable Mutations administrator 2 Views • 2 years ago

Corey J. Langer, MD; V****iliki Papadimitrakopoulou, MD; and Hossein Borghaei, DO, elucidate the potential value of less common actionable mutations in determining appropriate treatment for patients with non–small cell lung cancer.
Gwen’s Fight with Non-Small Cell Lung Cancer
Gwen’s Fight with Non-Small Cell Lung Cancer administrator 7 Views • 2 years ago

Patient Points of View is a video series bringing individual stories to life by highlighting the uniqueness of each patient’s experience navigating their cancer journey.

Meet Gwen, a devoted wife, mother and grandmother living with non-small cell lung cancer (NSCLC), and a self-proclaimed fighter. She opens up about her journey, the importance of comprehensive biomarker testing, and the impact it had on her treatment planning.

Explore other patient points of view: https://www.youtube.com/playli....st?list=PL4Tuh0XPkCh

Learn more about Amgen Oncology:
https://www.amgenoncology.com/

Find Amgen Oncology on the Web:
Twitter: https://bit.ly/3nGSj6Y
LinkedIn: https://bit.ly/3MhCe10

#cancer #cancerpatient #patientstory #patientexperience #cancersurvivor #patientadvocate #biomarkertesting #genetictesting #biomarkers #nonsmallcelllungcancer #nsclc #patientstory #science


© 2023 Amgen, Inc. All rights reserved.



Find Amgen on the Web:
Facebook: https://bit.ly/35Xf09E
Instagram: https://bit.ly/2SYnTKJ
Twitter: https://bit.ly/2SW2cLq
LinkedIn: https://bit.ly/2xWbS17

ASCO 2023: highlights in non-small cell lung cancer
ASCO 2023: highlights in non-small cell lung cancer administrator 4 Views • 2 years ago

Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, gives an overview of influential lung cancer trials at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including overall survival findings from the Phase III ADAURA trial (NCT02511106), which ****essed osimertinib in non-small cell lung cancer (NSCLC) in the adjuvant setting. Dr Sabari additionally highlights results from the ALINA trial (NCT03456076) of alectinib in NSCLC. This interview took place at ASCO 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Presentation of Stage III Non–Small Cell Lung Cancer
Presentation of Stage III Non–Small Cell Lung Cancer administrator 2 Views • 2 years ago

Stephen Liu, MD, presents the case of a 62-year-old man with stage III non–small cell lung cancer and provides insight into management and prognosis.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/

Non-Small Cell Lung Cancer (NSCLC) Immunotherapy: Advancing Hope
Non-Small Cell Lung Cancer (NSCLC) Immunotherapy: Advancing Hope administrator 3 Views • 2 years ago

SITC presents NSCLC Immunotherapy: Advancing Hope, the newest in a series of videos focusing on immunotherapy for NSCLC patients. This video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting some of the FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials.

*This video was produced prior to the October 2016 FDA approvals of 1) TECENTRIQ® (atezolizumab, Genetech, Inc.) in patients whose disease progressed despite treatment with platinum-containing chemotherapy and 2) KEYTRUDA® (pembrolizumab; Merck & Co., Inc.) as first-line therapy in patients whose tumors express high levels of PD-L1 on an FDA-approved test, without certain genetic mutations (EGFR or ALK). As a leader in the field of cancer immunotherapy research and education, SITC will continue to update this video series as additional immunotherapy treatments become available.

Access Companion Online Activity: https://www.cmeuniversity.com/....course/disclaimer/11

What is non-small cell lung cancer (NSCLC)?
What is non-small cell lung cancer (NSCLC)? administrator 2 Views • 2 years ago

Learn more about lung cancer at http://www.YouAndLungCancer.com
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 80% of lung cancers diagnosed every year. NSCLC has several sub categories. The most common sub category is called “adenocarcinoma” which makes up about half of all patients. Another category is called “squamous cell carcinoma” which makes up about a quarter of all patients. There are also other rarer subtypes such as “large cell carcinoma” and other neuroendocrine type of cancers.

Showing 41 out of 42